MoonLake Immunotherapeutics (MLTX) Retained Earnings (2020 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Retained Earnings of $786.3 million for Q1 2026, up 32841.47% year-over-year from N/an in Q1 2025, and up 269.86% quarter-over-quarter from -$462.9 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Retained Earnings (2020 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at $786.3 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 32841.47% year-over-year to $786.3 million; the TTM figure through Mar 2026 stood at $786.3 million (up 32841.47% YoY), while the FY2025 annual figure was -$462.9 million, down 9363.78% from the prior year.
- Retained Earnings for Q1 2026 stood at $786.3 million, up from -$462.9 million in the prior quarter.
- The five-year high for Retained Earnings was $786.3 million in Q1 2026, with the low at -$462.9 million in Q4 2025.
- The 5-year median for Retained Earnings is $3.3 million (2024), against an average of $173.5 million.
- The sharpest annual moves came in 2023 and 2026: Retained Earnings plunged 33340.86% in 2023, then surged 32841.47% in 2026.
- MoonLake Immunotherapeutics' Retained Earnings stood at $350946.0 in 2022, then slumped by 33340.86% to -$116.7 million in 2023, then soared by 104.28% to $5.0 million in 2024, then tumbled by 9363.78% to -$462.9 million in 2025, then surged by 269.86% to $786.3 million in 2026.
- Business Quant data shows MLTX's Retained Earnings at $786.3 million in Q1 2026, -$462.9 million in Q4 2025, and $689.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 1.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.02 Bn |
| Mar 31, 2026 | 786.31 Mn |
| Dec 31, 2025 | -462.91 Mn |
| Sep 30, 2025 | 689.11 Mn |
| Jun 30, 2025 | 683.96 Mn |
| Mar 31, 2025 | 2.39 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 675.34 Mn |
| Jun 30, 2024 | 3.26 Mn |
| Mar 31, 2024 | 670.19 Mn |
| Dec 31, 2023 | -116.66 Mn |
| Sep 30, 2023 | 2.88 Mn |
| Jun 30, 2023 | 35,124.00 |
| Mar 31, 2023 | -89.66 Mn |
| Dec 31, 2022 | 350,946.00 |
| Sep 30, 2022 | 123.83 Mn |
| Jun 30, 2022 | -58.68 Mn |
| Mar 31, 2022 | 34.16 Mn |
| Dec 31, 2021 | -53.64 Mn |
| Sep 30, 2021 | -4.84 Mn |